GlassScriptPhysician profile
Marga C Dizon
NPI 1871185124
$1,665.97
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $995.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $265.37 | 2021-2022 | |
| Insmed, INC. | $114.20 | 2021-2022 | |
| Grifols USA, LLC | $101.61 | 2021-2022 | |
| Genzyme Corporation | $74.11 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.02 | 2021-2022 | |
| Electromed, INC. | $42.35 | 2021-2022 | |
| Mylan Specialty L.P. | $40.80 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.92 | 2022 | |
| Amgen INC. | $31.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.05 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.93 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marga Dizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.